Cyient DLM (CYIENTDLM) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
15 Oct, 2026Executive summary
Q2 FY26 revenue was ₹3,106.34M, down 20.2% YoY after completion of a large order; EBITDA was ₹312M, while backlog reached ₹22,911M.
EBITDA margin improved 192 bps YoY to 10.0%; reported PAT was ₹321.45M, including a ₹195.75M earnout reversal.
H1 order intake grew 130% YoY, and Q2 added two global customers in future mobility and EV charging.
Unaudited consolidated and standalone results were approved; Dr. Ganesh Natarajan was appointed Independent Director for a three-year term, subject to shareholder approval.
Financial highlights
H1 revenue declined 9.0% YoY to ₹5,891M; EBITDA rose 9.0% to ₹563M, with margin up 157 bps to 9.5%.
Q2 reported PAT rose 108.0% YoY to ₹321M; normalized PAT was ₹126M, down 18.7% YoY.
H1 reported PAT increased 52.1% to ₹396M; normalized PAT declined 23.1% to ₹200M.
Q2 basic EPS was ₹4.05, versus ₹0.94 in Q1 FY26; total comprehensive income was ₹333.05M.
Outlook and guidance
H2 outlook points to continued order momentum and margin improvement; year-on-year growth is expected to resume from Q4 FY26, with a positive FY27 setup.
Large deals were at advanced pipeline stages; H1 order intake grew 130% YoY.
Priorities include account mining, India-market focus, Build-to-Specification capabilities, and expansion in medical, industrial and EV markets.
Acquisition targets in NAM and EMEA are being evaluated to expand client proximity, geographic footprint and capabilities; no formal FY27 guidance has been issued.
Latest events from Cyient DLM
- Revenue rose 43.2% as Aerospace & Defense growth lifted FY24 results.CYIENTDLM
Q4 23/24 - Revenue and backlog hit records, but investment and mix weighed on Q2 margins.CYIENTDLM
Q2 26/27 - Q2 FY25 revenue up 33.4% YoY, with Altek acquisition boosting US growth and future EPS.CYIENTDLM
Q2 24/25 - Altek lifted Q3 revenue 38.4%, while adjusted PAT fell 9.8%.CYIENTDLM
Q3 24/25 - FY25 growth accelerated with Altek; top-customer softness weighed on Q4 standalone revenue.CYIENTDLM
Q4 24/25 - Record order intake lifted backlog as EBITDA grew and net profit declined.CYIENTDLM
Q1 25/26 - Backlog reached ₹23,494 Mn as normalized EBITDA margin rose to 10.2%.CYIENTDLM
Q3 25/26 - Record orders and improved normalized margins cushion FY26 revenue decline.CYIENTDLM
Q4 25/26 - Revenue rose 34.3%, PAT more than doubled and order book reached a record.CYIENTDLM
Q1 26/27